Clinical Trial Update: Ruxolitinib in Operable Head and Neck Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating ruxolitinib in operable head and neck squamous cell carcinoma was terminated, with results posted on 2024-10-30.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: University of California, San Francisco | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2024-10-30